Menopause Specialty Drives Higher Reimbursement

Specialty care turns a routine video visit into a higher value medical encounter. Midi is not selling fast urgent care visits, it is running an in network menopause clinic with trained nurse practitioners, OB GYN oversight, longer 45 to 60 minute first visits, recurring follow ups every 6 to 12 weeks, prescribing, labs, imaging, and medication management. That clinical depth supports higher reimbursement than broad telehealth platforms built around shorter, lower acuity visits.

• General telehealth has historically traded scale for lower revenue per patient. In telehealth comparables, platforms like Teladoc are described as highly scalable but low ARPU, while Midi is built around chronic, specialist care where each patient generates repeated covered visits and refill activity over years.
  3 sacra 5 sacra
• Midi also avoids the weakest paying part of the market. Its coverage is centered on major commercial plans and it does not participate in Medicaid programs, which keeps the patient mix tilted toward better reimbursed visits. That is a meaningful contrast with competitors like Elektra that also cover Medicare and Medicaid populations.
  2 sacra 6 joinmidi
• Cash pay menopause platforms prove there is willingness to spend for specialist care, but they monetize differently. Alloy charges an annual fee with monthly prescriptions, and Evernow sells memberships and self pay visits. Midi instead pushes that specialist value through insurer contracts and employer channels, which can support larger reimbursed visit economics at scale.
  2 sacra 8 evernow 9 evernow

The next step is for menopause care to be treated less like a niche benefit and more like a standard covered specialty. If Midi keeps proving better screening, retention, and symptom outcomes, payers and employers will have a reason to preserve premium rates, and broad telehealth platforms will be forced to match specialist depth rather than just add menopause as another menu item.